1. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil;Diasio;Pharmacology,2000
2. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phopsphorylase;Salonga;Clin. Cancer Res.,2000
3. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the -antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice;Ishikawa;Clin. Cancer Res.,1999
4. Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidilate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells;Kirihara;Int. J. Oncol.,1999
5. P53 point mutations and thymidilate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival;Lenz;Clin. Cancer Res.,1998